Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lisdexamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisdexamfetamine SCHEMBL158949 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL25674417 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL31439237 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL12947679 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL579061 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL31173641 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| SCHEMBL21657924 | 0.99 | MMP2 (0.63) | MMP2NPC1RAB9ALTA4HLMNA | |
| SCHEMBL1844896 | 0.96 | MMP2 (0.59) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL970534 | 0.95 | MMP2 (0.59) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL678421 | 0.95 | MMP2 (0.59) | MMP2NPC1RAB9ALTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723589-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20200029892-A1 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | THE GENERAL HOSPITAL CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-20190290196-A1 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | THE GENERAL HOSPITAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-10299720-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | THE GENERAL HOSPITAL CORPORATION (US) | 2019-05-28 | — | — | US | disclosed |
| US-20150196249-A1 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-8487134-B2 | Process for the synthesis of amphetamine derivatives | ARCHIMICA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110196173-A1 | Process for the Synthesis of Amphetamine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2011-08-11 | — | — | US | disclosed |
| WO-2010042120-A1 | PROCESS FOR THE SYNTHESIS OF AMPHETAMINE DERIVATIVES | ARCHIMICA, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723589-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | ACHE, ADORA2A, COMT | MMP2 3821/4885NPC1 3561/4885RAB9A 836/4885 |
| US-20110196173-A1 | Process for the Synthesis of Amphetamine Derivatives | GNPAT, DDT, NAAA | MMP2 3220/4885NPC1 3262/4885RAB9A 2106/4885 |
| US-10299720-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | ACHE, ADORA2A, ADORA1 | MMP2 3838/4885NPC1 3078/4885RAB9A 770/4885 |
| US-20190290196-A1 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | ACHE, ADORA2A, ADORA1 | MMP2 3833/4885NPC1 3121/4885RAB9A 786/4885 |
| US-20200029892-A1 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | ACHE, ADORA2A, COMT | MMP2 3821/4885NPC1 3561/4885RAB9A 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.